GLP-1 / Metabolic

Liraglutide

FDA approved

Also known as: Victoza, Saxenda

First-generation GLP-1 — daily injection, robust safety record, foundational to the category.

Open in AppAsk AI Advisor

Mechanism

GLP-1 receptor agonist. First-generation GLP-1 — daily injection, robust safety record, foundational to the category. For full mechanism, dosing protocol, and stacking guidance, ask the AI Advisor or open the compound in-app.

Peer-Reviewed Studies (2)

Liraglutide 3.0 mg in Weight Management (SCALE)

NEJM · 2015

8.0% weight loss vs 2.6% placebo at 56 weeks.

PubMed PMID 26132939 →

Liraglutide and Cardiovascular Outcomes in T2D (LEADER)

NEJM · 2016

13% reduction in MACE in 9,340 high-risk T2D patients.

PubMed PMID 27295427 →

Related Compounds

Semaglutide

The GLP-1 that started it all — weekly injection, durable weight loss, restored insulin signaling.

Tirzepatide

The first dual incretin — superior to GLP-1 alone on weight, glucose, and metabolic markers.

Retatrutide

Triple agonist — three receptors, one molecule, the highest weight loss efficacy ever recorded.

CagriSema

Amylin meets GLP-1 — dual mechanism that addresses what semaglutide alone misses.